Diario Judío México - Tel Aviv — ’s disease is a debilitating neurodegenerative disease, affecting everything from speech, posture and gait to digestion, sleep, impulse control and cognition. Therapies exist that alleviate some symptoms of the disease, but there is still no cure for ’s, which affects close to one million Americans and 10 million people worldwide.

A new Tel Aviv University study unveils a novel method for detecting the aggregation of the protein alpha-synuclein, a hallmark of ’s disease. With this knowledge, caregivers could introduce treatment that has the potential to significantly delay disease progression.

By the time a patient is diagnosed with ’s disease, 50 percent to 80 percent of the dopaminergic cells in the part of the brain called substania nigra are already dead, possibly due to development of toxicity as result of alpha-synuclein aggregation. “We have developed a new method for tracking early stages of aggregation of alpha-synuclein using super-resolution microscopy and advanced analysis,” says Prof. Uri Ashery, co-author of the study and head of TAU’s Sagol School of Neuroscience and TAU’s George S. Wise Faculty of Life Sciences. The research was published in Acta Neuropathologica on May 31.

“Together with our collaborators at Cambridge University, who developed a special mouse model for ’s disease, we were able to detect different stages of the aggregation of this protein,” Prof. Ashery explains. “We correlated the aggregation with the deteriorating loss of neuronal activity and deficits in the behavior of the mice.”

“This is extremely important because we can now detect early stages of alpha-synuclein aggregation and monitor the effects of drugs on this aggregation,” says Dr. Dana Bar-On of the Sagol School of Neuroscience, a co-author of the study. “We hope that this research can be implemented for use in the early diagnosis of ’s in patients. We’re currently working to implement the methods in a minimally invasive manner with ’s patients.”

The researchers, in collaboration with the Max Planck Institute in Gottingen and Ludwig-Maximilians-Universität München, were able to illustrate the effect of a specific drug, anle138b, on this protein aggregation and correlated these results with the normalization of the Parkinson’s phenotype in the mice, according to Prof. Ashery. “This is a significant step forward in the world of Parkinson’s research,” he says.

The researchers are planning to expand their research to family members of Parkinson’s disease patients. “By detecting aggregates using minimally invasive methods in relatives of Parkinson’s disease patients, we can provide early detection and intervention and the opportunity to track and treat the disease before symptoms are even detected,” Prof. Ashery concludes.

American Friends of Tel Aviv University supports ’s most influential, comprehensive and sought-after center of higher learning, Tel Aviv University (TAU). TAU is recognized and celebrated internationally for creating an innovative, entrepreneurial culture on campus that generates inventions, startups and economic development in . TAU is ranked ninth in the world, and first in , for producing start-up founders of billion-dollar companies, an achievement that surpassed several Ivy League universities. To date, 2,500 US patents have been filed by Tel Aviv University researchers — ranking TAU #1 in , #10 outside of the US and #43 in the world.


Deja tu Comentario

A fin de garantizar un intercambio de opiniones respetuoso e interesante, DiarioJudio.com se reserva el derecho a eliminar todos aquellos comentarios que puedan ser considerados difamatorios, vejatorios, insultantes, injuriantes o contrarios a las leyes a estas condiciones. Los comentarios no reflejan la opinión de DiarioJudio.com, sino la de los internautas, y son ellos los únicos responsables de las opiniones vertidas. No se admitirán comentarios con contenido racista, sexista, homófobo, discriminatorio por identidad de género o que insulten a las personas por su nacionalidad, sexo, religión, edad o cualquier tipo de discapacidad física o mental.
Artículo anteriorEntre Palacios, Libros y Arte Culinario: Viena
Artículo siguienteAgencias de innovación de Israel y Brasil firman nuevos proyectos de cooperación
Es la representación de la Universidad de Tel Aviv en México desde el año 1980. La Asociación Amigos de la Universidad de Tel Aviv en México organiza conferencias, simposios, congresos y otros eventos de alto nivel académico con personalidades relevantes de la Universidad de Tel Aviv y México, ofreciendo variados espacios de información y encuentros de reflexión de alto nivel cultural y académico. Misión: Difundir los logros de la Universidad de Tel Aviv en lo referente a los avances de las ciencias, la cultura, las artes, la conservación del medio ambiente y la paz. Realizar conferencias, simposios, congresos y otros eventos de alto nivel académico. Organizar actividades académicas con personalidades relevantes de la Universidad de Tel Aviv que visitan nuestro país. Firmar acuerdos de colaboración con los principales centros de estudio e investigación mexicanos. Promover el intercambio de estudiantes. Editar publicaciones referidas al desarrollo tecnológico, científico, humanístico y educativo alcanzado por la Universidad de Tel Aviv. Ha firmado acuerdos de colaboración con los principales centros de estudio e investigación en México.